Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21408159 | 0.81 | HSD17B10 (0.42) | HSD17B10HPGDSMN1; SMN2NPC1HSD11B1 | |
| SCHEMBL16031033 | 0.80 | HSD17B10 (0.42) | HSD17B10HPGDSMN1; SMN2NPC1HSD11B1 | |
| SCHEMBL16031037 | 0.80 | HSD17B10 (0.42) | HSD17B10HPGDSMN1; SMN2NPC1HSD11B1 | |
| SCHEMBL16148112 | 0.80 | HSD17B10 (0.42) | HSD17B10HPGDSMN1; SMN2NPC1HSD11B1 | |
| SCHEMBL16031035 | 0.77 | HSD17B10 (0.39) | HSD17B10HPGDSMN1; SMN2NPC1HSD11B1 | |
| SCHEMBL24845877 | 0.74 | HSD17B10 (0.39) | HSD17B10MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL27172955 | 0.74 | HSD17B10 (0.39) | HSD17B10MEN1KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL21408122 | 0.74 | USP2 (0.39) | HSD17B10HPGDSMN1; SMN2HSD11B1NR1H2 | |
| SCHEMBL1643826 | 0.74 | USP2 (0.39) | HSD17B10HPGDSMN1; SMN2HSD11B1NR1H2 | |
| SCHEMBL17631948 | 0.74 | HSD17B10 (0.38) | HSD17B10HPGDSMN1; SMN2HSD11B1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828182-B1 | THERAPEUTIC PYRAZOLO[3,4-B]PYRIDINES AND INDAZOLES | WARNER LAMBERT CO (US) | 2010-03-10 | — | — | EP | disclosed |
| US-7485636-B2 | Therapeutic pyrazolo[3,4-b]pyridines and indazoles | PFIZER INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080293715-A1 | Therapeutic Pyrazolo[3,4-b]Pyridines and Indazoles | WARNER LAMBERT COMPANY LLC (US) | 2008-11-27 | — | — | US | disclosed |
| US-7423054-B2 | Therapeutic pyrazolo[3,4-b]pyridines and indazoles | WARNER LAMBERT COMPANY LLC (US) | 2008-09-09 | — | — | US | disclosed |
| CN-101111494-A | Therapeutic pyrazolo[3,4-b]pyridines and indazoles | WARNER LAMBERT CO (US) | 2008-01-23 | — | — | CN | disclosed |
| EP-1828182-A2 | THERAPEUTIC PYRAZOLO[3,4-B]PYRIDINES AND INDAZOLES | Warner-Lambert Company LLC (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20060217376-A1 | Therapeutic pyrazolo[3,4-b]pyridines and indazoles | WARNER-LAMBERT COMPANY LLC | 2006-09-28 | — | — | US | disclosed |
| WO-2006056873-A2 | THERAPEUTIC PYRAZOLO[3,4-B] PYRIDINES AND INDAZOLES | WARNER-LAMBERT COMPANY LLC (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20060116376-A1 | Therapeutic pyrazolo[3,4-B]pyridines and indazoles | WARNER-LAMBERT COMPANY LLC | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293715-A1 | Therapeutic Pyrazolo[3,4-b]Pyridines and Indazoles | P2RX3, P2RX4, ACHE | HSD17B10 3445/4885MEN1 4701/4885KMT2A 3451/4885 |
| US-20060116376-A1 | Therapeutic pyrazolo[3,4-B]pyridines and indazoles | P2RX3, P2RX4, ACHE | HSD17B10 3445/4885MEN1 4701/4885KMT2A 3451/4885 |
| US-20060217376-A1 | Therapeutic pyrazolo[3,4-b]pyridines and indazoles | P2RX3, P2RX4, ACHE | HSD17B10 3445/4885MEN1 4701/4885KMT2A 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.